Focus on Prostate Cancer

According to NIH’s National Cancer Institute, Prostate cancer is the third most common cancer in the US as of February 2019 sorted by estimated new cases. There were 174,650 estimated new cases which were estimated to result in 31,620 deaths.
 
There are eight investigational drugs targeting Prostate Cancer in the Pharmaceutical Pipeline Tracker. Seven are in Phase III trials while the remaining drug is in multiple Phase II Trials. None of the drugs have PDUFA Dates at this time and the FDA has not assigned any Priority Designations to any of the eight drugs. Of the eight drugs Genentech/Array BioPharma's ipatasertib is available in the EU while Steba Biotech's padeliporfin (Tookad) is approved in the EU.